- Conditions
- Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma
- Interventions
- Atovaquone, Biopsy, Computed Tomography, Paracentesis
- Drug · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 2,188
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Renal Cell Carcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent Melanoma, Recurrent Renal Cell Carcinoma, Refractory Melanoma, Refractory Renal Cell Carcinoma, Sarcoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Pembrolizumab, Ziv-Aflibercept
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Bethesda, Maryland • Boston, Massachusetts
- Conditions
- Endometrial Cancer, Ovarian Cancer
- Interventions
- Copanlisib, fulvestrant
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Interventions
- temsirolimus
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
- Interventions
- Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Sacituzumab Govitecan
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 10
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 7 more
- Conditions
- Cancer
- Interventions
- DNA analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review, questionnaire administration, assessment of therapy complications, evaluation of cancer risk factors
- Genetic · Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Ovarian Cancer, Peritoneal Primary Cancer, Fallopian Tube Cancer
- Interventions
- healing touch, massage therapy, hypnosis, Standard chemotherapy
- Other · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Mixed Germ Cell Tumor, Ovarian Teratoma, Ovarian Yolk Sac Tumor, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma, Testicular Seminoma, Testicular Teratoma, Testicular Yolk Sac Tumor
- Interventions
- Laboratory Biomarker Analysis, Questionnaire Administration
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 19 Years
- Enrollment
- 932 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non Small Cell Lung Cancer, Lung Cancer, Melanoma, Ovarian, NSCLC
- Interventions
- SI-B036
- Drug
- Lead sponsor
- SystImmune Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Orlando, Florida • Sarasota, Florida + 4 more
- Conditions
- Ovarian Cancer
- Interventions
- Fourier transform ion cyclotron resonance mass spectrometry, chromatography, diagnostic laboratory biomarker analysis, questionnaire administration
- Other
- Lead sponsor
- Pine Street Foundation
- Other
- Eligibility
- 21 Years to 120 Years · Female only
- Enrollment
- 109 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2012
- U.S. locations
- 4
- States / cities
- San Anselmo, California • San Francisco, California • Orono, Maine
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, Kidney Cancer, Liver Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Sarcoma
- Interventions
- colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study, conventional surgery
- Biological · Other · Procedure
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Ovarian Cancer, Peritoneal Cavity Cancer
- Interventions
- Ad5CMV-p53 gene
- Biological
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 1999
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
- Interventions
- maplirpacept (PF-07901801), Pegylated Liposomal Doxorubicin (PLD)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 18
- States / cities
- Santa Monica, California • Miami, Florida • Orlando, Florida + 10 more
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Neoplasm of Unknown Primary, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 798 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1006
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more
- Conditions
- Relapsed/Refractory Ovarian Carcinoma
- Interventions
- NTB-928
- Drug
- Lead sponsor
- TeneoSeven, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Omaha, Nebraska • Lake Success, New York + 1 more
- Conditions
- Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Interventions
- Tulmimetostat, Enzalutamide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 22
- States / cities
- Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 15 more
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- paclitaxel poliglumex
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma, Malignant Rhabdoid Tumor of Ovary
- Interventions
- Tazemetostat
- Drug
- Lead sponsor
- Epizyme, Inc.
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 13 more
- Conditions
- Ovarian Neoplasms
- Interventions
- Not listed
- Lead sponsor
- Susan Lutgendorf
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2026
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • St Louis, Missouri
- Conditions
- Advanced Ovarian Cancer, Triple Negative Breast Cancer
- Interventions
- Atezolizumab, RO6870810
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Oklahoma City, Oklahoma • Nashville, Tennessee
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
- Interventions
- bortezomib, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Wild-type Reovirus
- Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms
- Interventions
- Sofe-M, bevacizumab, carboplatin, Itraconazole, pembrolizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • La Jolla, California • Atlanta, Georgia + 7 more
- Conditions
- Primary Peritoneal Cavity Cancer, Stage I Endometrial Carcinoma, Stage I Ovarian Epithelial Cancer, Stage IA Cervical Cancer, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage II Ovarian Epithelial Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Endometrial Carcinoma, Stage IV Ovarian Epithelial Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
- Interventions
- EF5
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania